Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00649441 · ClinicalTrials.gov registry record · Phase 1
Fasting Study of Quinapril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg to Accuretic™ Tablets 20 mg/25 mg
A Phase 1 study, sponsored by Mylan Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
NCT00649441: Completed Phase 1 study, sponsored by Mylan Pharmaceuticals.
NCT00649441 is a Phase 1 study that has completed, run by Mylan Pharmaceuticals. The registered enrollment target is 60 participants, roughly in line with the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00649441, a Phase 1 study, has completed, sponsored by Mylan Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
Study Summary
The objective of this study was to investigate the bioequivalence of Mylan's quinapril HCl and hydrochlorothiazide 20 mg/25 mg tablets to Parke-Davis' Accuretic™ 20 mg/25 mg tablets following a single, oral 20 mg/25 mg (1 x 20 mg/25 mg) dose administered under fasting conditions.
Interventions
- DRUG Quinapril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg
- DRUG Accuretic™ Tablets 20 mg/25 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2003-08 |
| Est. Completion | 2003-09 |
| Phase | Phase 1 |
What the finished NCT00649441 record still lists
NCT00649441 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, roughly in line with the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target.
The record links to 0 conditions, and to 2 interventions - of which Quinapril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg is the first listed.
NCT00649441 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00649441 about?
NCT00649441 is a clinical study titled "Fasting Study of Quinapril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg to Accuretic™ Tablets 20 mg/25 mg". The objective of this study was to investigate the bioequivalence of Mylan's quinapril HCl and hydrochlorothiazide 20 mg/25 mg tablets to Parke-Davis' Accuretic™ 20 mg/25 mg tablets following a single, oral 20 mg/25 mg (1 x 20 mg/25 mg) dose administered under fasting conditions.
What is the current status of trial NCT00649441?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2003-08. Estimated completion is 2003-09.
What interventions are being tested in trial NCT00649441?
The interventions under investigation include: Quinapril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg (DRUG), Accuretic™ Tablets 20 mg/25 mg (DRUG).
Who is sponsoring clinical trial NCT00649441?
This trial is sponsored by Mylan Pharmaceuticals, which has 146 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00649441's enrollment target sits among peer trials
60 831st of 2000 higher than 1,106 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia